Analyst Ratings For NASDAQ:EIGR – Eiger Biopharmaceuticals (NASDAQ:EIGR)
Today, Piper Jaffray raised its price target on NASDAQ:EIGR – Eiger Biopharmaceuticals (NASDAQ:EIGR) to per share.
Some recent analyst ratings include
- 5/17/2018-Wedbush Reiterated Rating of Outperform.
- 5/9/2018-B. Riley initiated coverage with a Buy ➝ Buy rating.
- 1/3/2018-Ladenburg Thalmann initiated coverage with a Buy ➝ Buy rating.
- 10/19/2017-Roth Capital initiated coverage with a Buy ➝ Buy rating.
Recent Insider Trading Activity For NASDAQ:EIGR – Eiger Biopharmaceuticals (NASDAQ:EIGR)
NASDAQ:EIGR – Eiger Biopharmaceuticals (NASDAQ:EIGR) has insider ownership of 7.90% and institutional ownership of 70.33%.
- On 4/2/2018 Joanne Quan, Insider, sold 4,000 with an average share price of $10.00 per share and the total transaction amounting to $40,000.00.
- On 9/1/2017 Jeffrey S Glenn, Director, bought 15,000 with an average share price of $9.53 per share and the total transaction amounting to $142,950.00.
- On 11/18/2016 Jeffrey S Glenn, Director, bought 15,460 with an average share price of $12.74 per share and the total transaction amounting to $196,960.40.
- On 8/18/2016 James P Shaffer, Insider, bought 3,125 with an average share price of $15.70 per share and the total transaction amounting to $49,062.50.
- On 8/18/2016 Ventures Fund Vi L.P. Vivo, Major Shareholder, bought 187,500 with an average share price of $16.00 per share and the total transaction amounting to $3,000,000.00.
- On 6/22/2016 James H Welch, CFO, bought 2,500 with an average share price of $19.80 per share and the total transaction amounting to $49,500.00.
- On 6/13/2016 James P Shaffer, Insider, bought 1,250 with an average share price of $22.17 per share and the total transaction amounting to $27,712.50.
Recent Trading Activity for NASDAQ:EIGR – Eiger Biopharmaceuticals (NASDAQ:EIGR)
Shares of NASDAQ:EIGR – Eiger Biopharmaceuticals closed the previous trading session at 15.85 down -0.95 5.65% with 18.0 shares trading hands.